Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Retained Earnings: 2019-2024

Historic Retained Earnings for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to -$893.1 million.

  • Avidity Biosciences' Retained Earnings fell 69.52% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 69.52%. This contributed to the annual value of -$893.1 million for FY2024, which is 56.47% down from last year.
  • Per Avidity Biosciences' latest filing, its Retained Earnings stood at -$893.1 million for FY2024, which was down 56.47% from -$570.8 million recorded in FY2023.
  • Over the past 5 years, Avidity Biosciences' Retained Earnings peaked at -$66.5 million during FY2020, and registered a low of -$893.1 million during FY2024.
  • In the last 3 years, Avidity Biosciences' Retained Earnings had a median value of -$570.8 million in 2023 and averaged -$607.5 million.
  • Data for Avidity Biosciences' Retained Earnings shows a maximum YoY plummeted of 199.93% (in 2020) over the last 5 years.
  • Avidity Biosciences' Retained Earnings (Yearly) stood at -$66.5 million in 2020, then plummeted by 177.35% to -$184.5 million in 2021, then plummeted by 94.28% to -$358.5 million in 2022, then slumped by 59.19% to -$570.8 million in 2023, then slumped by 56.47% to -$893.1 million in 2024.